SARS-CoV-2 fusion protein vaccine/regimen
US12427191B1 · kind B1 · utility
Assignee
Inventor
Key dates
| Filing date | Apr 22, 2022 |
| Grant date | Sep 30, 2025 |
| Priority date | — |
| Expiry date | Aug 1, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/20034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A SARS-CoV-2 immunotherapeutic targeted fusion protein regimen or vaccine in which the extracellular domain (ecd) of the CD40L immunostimulatory protein, is attached individually to mRNA encoding a Selected Fragment of the Spike Protein (SFSP), representing a different functional feature and a different domain or domain region, or both of the Spike Protein, to generate 7 distinct SFSP/ecdCD40L translation units, each translation unit being converted into a SFSP/ecdCD40L fusion protein regimen or vaccine and all combined into a single fusion protein mixture or composition for injection, preferably inter-muscularly (im). Each fragment or peptide is designed to activate a humoral and cellular immune response to a different SFSP. Each SFSP fragment or peptide, as a vaccine strategy for the SARS-CoV-2 virus, has the capability to suppress the emergence of immunological escape mutants. The fusion protein mixture or composition of multiple fragments or peptides could be incorporated in any one of several delivery platforms such as an adenoviral expression vector or an mRNA platform.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.